undamentalytics Newsletter

Glimcher Laurie H M.D.: insider trades

Director at 3 companies we cover. No open-market purchases and 18 sales not made under a pre-set plan, reported from March 22, 2010 to March 17, 2021.

What happened after Glimcher Laurie H M.D.’s sales?

After their sales, the shares moved −2.5% against the index over 12 months on average (a negative figure means selling was the right call); 72% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Glimcher Laurie H M.D.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 18 −1.5% +0.7% 44% 10 −0.82 0.43 No reliable evidence
Sales, 12 months after the report 18 −2.5% −3.9% 72% 10 −1.21 0.26 No reliable evidence
Sales, 12 months after the trade 18 −2.8% −5.2% 72% 10 −1.32 0.22 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Waters Corporation WAT —015March 22, 2010November 4, 2019
Bristol Myers Squibb BMY —02March 20, 2012January 30, 2013
Analog Devices ADI —01March 17, 2021March 17, 2021

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 17, 2021March 16, 2021 ADI Sale $70,872 +3.5%−5.3%−8.8%
November 4, 2019November 1, 2019 WAT Sale $472,208 −6.3%−14.3%−6.6%
February 27, 2019February 26, 2019 WAT Sale $354,455 −17.5%−27.9%−28.7%
May 22, 2017May 19, 2017 WAT Sale $843,720 +1.1%−5.8%−5.0%
August 1, 2016July 28, 2016 WAT Sale $625,528 −10.6%−4.7%−5.4%
May 4, 2015May 1, 2015 WAT Sale $505,600 +4.7%+2.1%+4.2%
July 30, 2014July 29, 2014 WAT Sale $581,075 +3.1%+17.9%+17.7%
February 18, 2014February 13, 2014 WAT Sale $324,800 −12.9%−10.4%−9.9%
November 12, 2013November 8, 2013 WAT Sale $240,000 +8.7%−3.0%−4.9%
January 30, 2013January 30, 2013 BMY Sale $400,400 +4.5%+21.1%+20.3%
January 28, 2013January 25, 2013 WAT Sale $624,712 −6.7%−2.6%−9.8%
November 7, 2012November 6, 2012 WAT Sale $84,740 +0.4%−10.9%−9.9%
May 10, 2012May 9, 2012 WAT Sale $167,560 −11.7%−9.1%−8.8%
March 20, 2012March 16, 2012 BMY Sale $116,130 +8.8%+13.6%+11.7%
May 17, 2011May 13, 2011 WAT Sale $683,148 −10.0%−15.6%−16.3%
March 9, 2011March 8, 2011 WAT Sale $173,820 +10.8%−1.1%−3.6%
November 5, 2010November 4, 2010 WAT Sale $115,335 −9.8%−2.8%−2.0%
March 22, 2010March 19, 2010 WAT Sale $97,980 +12.6%+14.0%+16.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Glimcher Laurie H M.D. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.